Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Modified recombinant allergens for safer immunotherapy.

Fátima Ferreira¹, Peter Briza, Daniela Inführ

¹Department of Molecular Biology, University of Salzburg, A-5020 Salzburg, Austria. fatima.ferreira@sbg.ac.at

Inflammation & Allergy Drug Targets

|April 15, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sex-specific associations between long-term exposure to ambient air pollution and the cardiac conduction system - a longitudinal analysis of the KORA cohort.

International journal of hygiene and environmental health·2026

Same author

Infrastructure and policy reforms to facilitate collaboration in medical research.

Nature reviews. Nephrology·2026

Same author

Respiratory signal extraction from the electrocardiogram for risk stratification in cardiac patients.

European heart journal. Digital health·2026

Same author

Ozone alters the allergenicity of Ambrosia artemisiifolia pollen in a dose-dependent manner.

Environment international·2026

Same author

Multi-country IgE reactivity determination of isoforms of the <i>Blomia tropicalis</i> mite allergen Blo t 2 revealed a potential biomarker of asthma severity.

Frontiers in immunology·2026

Same author

Maternal-infant immune signatures in infants at risk for SARS-CoV-2-associated neurodevelopmental disorders.

Communications biology·2026

Same journal

Editorial. Inflammasomes--In Health and Diseases.

Inflammation & allergy drug targets·2016

Same journal

Inducible Nitric Oxide Synthase Expression in Liver Injury: Liver Protective Effects on Primary Rat Hepatocytes.

Inflammation & allergy drug targets·2016

Same journal

Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases.

Inflammation & allergy drug targets·2016

Same journal

A Systematic Review of the Molecular Mechanisms of Uranium -Induced Reproductive Toxicity.

Inflammation & allergy drug targets·2016

Same journal

Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance.

Inflammation & allergy drug targets·2016

Same journal

6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.

Inflammation & allergy drug targets·2016

See all related articles

Recombinant allergens are modified to reduce allergic reactions and improve immunotherapy. Clinical trials show promising results for ragweed and birch pollen allergies, with genetic immunization as a future possibility.

Area of Science:

Immunology
Biotechnology
Allergy Research

Background:

Allergies are a growing global health concern.
Specific immunotherapy aims to improve safety and efficacy.
Recombinant allergen production offers new therapeutic avenues.

Purpose of the Study:

To review advancements in recombinant allergen modification for immunotherapy.
To explore genetic and chemical modification strategies.
To assess the clinical efficacy and safety of modified allergens.

Main Methods:

Genetic modification of allergens to create hypoallergens (mutants, fragments, chimeras).
Chemical modification of recombinant allergens (e.g., allergen-ISS conjugates, allergoids, maleylation).
Clinical evaluation of modified allergen preparations in human trials and animal studies.

Related Experiment Videos

Main Results:

Allergen-ISS conjugates mask IgE epitopes and induce a Th1 immune response.
Hypoallergen preparations (e.g., Amb a 1-ISS, Bet v 1 fragments) show efficacy and safety in clinical trials.
Genetic immunization demonstrates potential for future allergy treatment.

Conclusions:

Modified recombinant allergens represent a promising strategy for safer and more effective allergy immunotherapy.
Clinical studies support the use of specific modified allergens for treating ragweed and birch pollen allergies.
Further research, including genetic immunization, holds potential for advancing allergy treatment.